Aminazin - Instructions For Use, Price, Reviews, Tablets, Analogues

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Aminazine

Aminazin: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. Use in childhood
11. 11. In case of impaired renal function
12. 12. For violations of liver function
13. 13. Use in the elderly
14. 14. Drug interactions
15. 15. Analogs
16. 16. Terms and conditions of storage
17. 17. Terms of dispensing from pharmacies
18. 18. Reviews
19. 19. Price in pharmacies

Latin name: Aminazine

ATX code: N05AA01

Active ingredient: chlorpromazine (chlorpromazine)

Manufacturer: PJSC "Valenta Pharmaceuticals" (PJSC "Valenta Pharm") (Russia), Novosibkhimpharm (Russia)

Description and photo update: 2019-09-09

Prices in pharmacies: from 132 rubles.

Buy

Aminazine is a sedative antipsychotic.

Release form and composition

• film-coated tablets: round biconvex, color of the shell for a dosage of 25 mg - white with a yellowish tinge, for a dosage of 50 mg - brown-pink, for a dosage of 100 mg - from reddish-brown to brown; the core at the break is white or almost white (10 pcs. in blisters: 25 mg tablets - in a cardboard box 1, 2 or 3 packages, 50 mg and 100 mg tablets - in a cardboard box 1 or 3 packages);
• pills: spherical, color depends on the dosage: pills 25 mg - white, pills 50 mg - brown-pink with darker splashes, 100 mg pills - brown with darker splashes (10 pcs. in blisters, in a cardboard box 3, 5 or 10 packs For hospitals: in a cardboard box or in a plastic film bag, 100 blisters each; in a polymer can with a parchment / parchment / waxed paper bag: 25 mg dragee - 3200 pcs. ± 5%, 50 mg pills - 2285 pcs. ± 5%, 100 mg pills - 1600 pcs. + 5%, 18 polymer cans in shipping containers);
• solution for intravenous (i / v) and intramuscular (i / m) administration: colorless or weakly colored transparent liquid (1, 2, 5 or 10 ml in ampoules: 10 ampoules in a cardboard box with an opening knife / ampoule scarifier, or in a blister strip of 5 or 10 ampoules, in a cardboard box 1 or 2 blister packs with an opening knife / ampoule scarifier Packages with ampoules equipped with a break ring or a break point do not contain an opening knife / ampoule scarifier).

Each pack also contains instructions for the use of Aminazin.

Composition of 1 tablet:

• active substance: chlorpromazine hydrochloride (in terms of 100% chlorpromazine) - 25, 50 or 100 mg;
• auxiliary ingredients: potato starch, MCC (microcrystalline cellulose), lactose monohydrate, copovidone, croscarmellose sodium, magnesium stearate;
• tablet shell 25 mg: Opadray II 85F38209 (partially hydrolyzed polyvinyl alcohol - 40%, macrogol-3350 - 20.2%, talc - 14.8%, titanium dioxide E171 - 24.89%, dye iron oxide yellow E172 - 0, eleven%);
• tablet shell 50 mg: Opadray II 85F240048 (partially hydrolyzed polyvinyl alcohol - 40%, macrogol-3350 - 20.2%, talc - 14.8%, titanium dioxide E171 - 22.7%, dye iron oxide red E172 - 1, 3%, dye iron oxide yellow E172 - 0.8%, dye iron oxide black E172 - 0.2%);
• tablet shell 100 mg: Opadray II 85F25509 (partially hydrolyzed polyvinyl alcohol - 40%, macrogol-3350 - 20.2%, talc - 14.8%, dye iron oxide red E172 - 20.2%, dye iron oxide black E172 - 4%, dye iron oxide yellow E172 - 0.8%).

Composition of 1 dragee:

• active substance: chlorpromazine hydrochloride (in terms of 100% chlorpromazine) - 25, 50 or 100 mg;
• auxiliary ingredients: gelatin, wax, talc, sucrose, starch syrup, titanium dioxide, sunflower oil, dye iron oxide red.

Composition of 1 ml solution:

• active substance: chlorpromazine hydrochloride (in terms of 100% chlorpromazine) - 25 mg;
• auxiliary ingredients: sodium disulfite, sodium sulfite anhydrous, sodium chloride, ascorbic acid, water for injection.

Pharmacological properties

Pharmacodynamics

The active ingredient of Aminazine - chlorpromazine, is a neuroleptic, belongs to the group of aliphatic phenothiazine derivatives, has antipsychotic efficacy.

Chlorpromazine has a pronounced antipsychotic and sedative effect, reduces motor activity, prolongs and enhances the effect of analgesics, hypnotics, local anesthetics, anticonvulsants and alcohol. Causes extrapyramidal disorders, stimulates the secretion of prolactin by the pituitary gland.

The antipsychotic effect of the substance is associated with blocking the postsynaptic dopaminergic receptors of the mesolimbic and mesocortical systems in the brain. It manifests itself in the elimination of such productive symptoms of psychosis as delusions and hallucinations. Aminazine inhibits psychotic fear and aggressiveness, suppresses various types of psychomotor agitation.

Sedation is due to blockade of adrenergic receptors of the reticular formation of the brain stem. The most important quality of chlorpromazine (when compared with other phenothiazines) is the severity of the sedative effect, which, with preserved consciousness, manifests itself in a weakening of conditioned reflex activity (primarily motor-defensive reflexes), a decrease in spontaneous motor activity, relaxation of skeletal muscles, a decrease in susceptibility to endo- and exogenous stimuli.

The antiemetic effect is provided by the blockade of dopamine D ₂ -receptors in the trigger zone of the vomiting center. In addition, Aminazine soothes hiccups, and its hypothermic effect is provided by blocking dopamine receptors in the hypothalamus and has a pronounced alpha-adrenergic blocking effect with a slight effect on cholinergic receptors. It reduces or eliminates the increase in blood pressure (blood pressure) and other effects caused by epinephrine, except for hyperglycemic, and also has a strong cataleptogenic effect.

Aminazine inhibits interoceptive reflexes, reduces capillary permeability, has a weak antihistamine and local irritant effectiveness. Under the influence of the drug, blood pressure decreases, and tachycardia can often develop.

Sedation occurs 15 minutes after the intramuscular injection of Aminazine.

Pharmacokinetics

Chlorpromazine is not completely absorbed after oral administration. C _max (maximum plasma concentration) is noted after 2–4 hours. As a result of i / m administration, the substance is absorbed well and quickly, the time to reach C _max is 1–2 hours.

It binds to plasma proteins at a level of more than 90% when taken orally, from 90 to 99% when administered intramuscularly.

Chlorpromazine is rapidly excreted from the circulatory system, and it accumulates unevenly in various organs. It passes well through the blood-brain barrier, while the concentration of the substance in the brain exceeds the plasma concentration. There is no direct correlation between the plasma concentration of chlorpromazine / metabolites and the therapeutic effect of the drug.

Chlorpromazine is extensively metabolized during the first pass through the liver (presystemic elimination), undergoing 30% oxidation, 30% hydroxylation, and 20% demethylation. Oxidized hydroxylated metabolites have pharmacological activity; they are inactivated by binding with glucuronic acid or upon further oxidation to form inactive sulfoxides.

The substance is excreted in urine and bile. The average half-life (T _1/2) is 30 hours. About 20% of the dose taken is excreted in 24 hours, 1–6% is excreted unchanged in the urine. After discontinuation of therapy, trace amounts of chlorpromazine metabolites in urine can be detected even after 12 months or more.

As a result of the high degree of protein binding, chlorpromazine is practically not susceptible to hemodialysis.

Indications for use

Aminazine film-coated tablets are recommended for the treatment of psychotic conditions (especially paranoid), including mania, hypomania and schizophrenia. As an auxiliary short-term course, this dosage form is prescribed for the treatment of anxious psychomotor agitation, violent and / or dangerous impulsive behavior.

Aminazine in the form of pills and a solution for intravenous and intramuscular administration is used:

• psychiatric practice: for the treatment of various types of psychotic conditions and psychomotor agitation in schizophrenia, manic agitation and manic-depressive psychosis, as well as other mental illnesses of various origins, accompanied by anxiety, fear, agitation, insomnia; in the case of mood disorders due to psychopathies, psychotic disorders in patients with organic disorders of the central nervous system (central nervous system) and epilepsy; for the relief of withdrawal symptoms with alcoholism / substance abuse;
• therapeutic, neurological and surgical practice: to enhance the effectiveness of analgesics for persistent pain, to soothe hiccups, in diseases, as a result of which, due to cerebrovascular accident, etc., muscle tone increases. Parenteral Aminazine is also used to relieve psychomotor agitation and as an antiemetic agent (including during surgery), in anesthesiology (as part of lytic mixtures) to lower body temperature.

In order to avoid complications parenterally, Aminazin must be used strictly as directed by a doctor!

Contraindications

Absolute contraindications for all forms of Aminazine release:

• inhibition of the central nervous system, including due to drug intoxication;
• coma of various etiologies;
• inhibition of the function of bone marrow hematopoiesis;
• pregnancy, breastfeeding;
• children's age: for tablets - up to 12 years, for pills - up to 3 years, for solution - up to 6 months;
• individual hypersensitivity to any components.

Aminazine tablets contain lactose, therefore, in this dosage form, the drug is contraindicated to prescribe to patients with lactose intolerance, lactase deficiency, glucose-galactose malabsorption.

Additional absolute contraindications for the drug in the form of pills:

• diseases of the liver, kidneys, hematopoietic organs, leading to a violation of their functions;
• traumatic brain injury;
• progressive systemic diseases of the brain / spinal cord;
• peptic ulcer of the stomach and duodenum in the acute phase;
• heart disease in the stage of decompensation (myocardial dystrophy, heart defects, rheumatic heart disease, etc.);
• diseases with a risk of thromboembolic complications;
• severe arterial hypotension;
• angle-closure glaucoma (due to the risk of increased intraocular pressure);
• bronchiectasis (BEB) in the stage of decompensation;
• myxedema;
• hyperplasia of the prostate.

Additional absolute contraindications for Aminazin in the form of a solution for intravenous and intramuscular administration:

• chronic heart failure (CHF) in the stage of decompensation;
• traumatic brain injury;
• arterial hypotension;
• progressive systemic diseases of the brain / spinal cord.

With caution, all dosage forms of Aminazin are prescribed to patients with active alcoholism (due to an increased risk of hepatotoxic reactions), Parkinson's disease, breast cancer, epilepsy, chronic diseases accompanied by respiratory failure (especially in childhood), cachexia, Reye's syndrome, vomiting (since the antiemetic effect of phenothiazines can mask vomiting caused by an overdose of other drugs) and in old age.

Additional relative contraindications for Aminazin in the form of a solution for intravenous and intramuscular administration: angle-closure glaucoma, hematopoietic disorders (pathological abnormalities of blood counts), hepatic / renal failure, prostatic hyperplasia with clinical manifestations, diseases with an increased risk of thromboembolic complications, Reye's syndrome in history (increased risk of developing hepatotoxicity in childhood and adolescence), myxedema.

Aminazine, instructions for use: method and dosage

This drug can be administered orally, intramuscularly, or intravenously.

Aminazine is prescribed according to the following scheme: adults 3-4 times a day, 10-100 mg, while the daily dose should not exceed 600 mg.

Children over 5 years old can use 1 / 3-1 / 2 of the adult dose.

For children 1-5 years old, a single dose is calculated by multiplying 500 μg of the drug by the child's weight, it should be taken every 4-6 hours.

A more accurate dosage regimen of Aminazine is determined by the attending physician, depending on the indications.

Side effects

• CNS: extrapyramidal disorders - akathisia, tremor, hyperkinesis, dystonic reactions, akinetic-rigid syndrome (amiostatic symptom complex), autonomic disorders, symptoms of drug-induced parkinsonism (muscle rigidity, hypokinesia, postural instability), early paroxysmal dyskinesia of the tongue neck, floor of the mouth and oculogyric crises, and with prolonged therapy - late or tardive dyskinesia; neuroleptic malignant syndrome (NMS), symptoms of which may be hyperthermia, muscle rigidity, mental disorders, somatic disorders caused by functional disorders of the autonomic nervous system; dizziness, drowsiness, sleep disorders, mental indifference, delayed reaction to external stimuli,mood lability, anxiety, agitation, insomnia, neuroleptic depression;
• cardiovascular system: tachycardia, orthostatic hypotension, cardiac arrhythmias (ventricular arrhythmias, including the "feast" type, the risk of which is higher in patients with initial bradycardia, hypokalemia, prolonged QT interval, heart disease in history, in the elderly age and while taking Aminazine with tricyclic antidepressants), changes in T and U waves, lengthening of the QT interval, venous thromboembolism (including pulmonary thromboembolism and deep vein thrombosis);
• respiratory system: nasal congestion, respiratory depression;
• Gastrointestinal tract (gastrointestinal tract): nausea / vomiting, diarrhea, dry mouth, constipation or ileus, anorexia;
• hepatobiliary system: cholestatic jaundice, liver damage, mainly cholestatic, hepatocellular or mixed (the onset of jaundice requires the abolition of chlorpromazine);
• genitourinary system: dysuria, oliguria, impotence, frigidity, amenorrhea, oligomenorrhea, priapism;
• endocrine system: galactorrhea, hyperprolactinemia, gynecomastia;
• organs of hematopoiesis: increased blood clotting, lymphopenia, anemia, leukopenia, agranulocytosis (it is recommended to control the blood picture);
• sense organs: clouding of the cornea and lens, accommodation disturbances;
• skin: photosensitivity, pigmentation, melanosis;
• immune system: hypersensitivity reactions from the mucous membranes and skin, facial edema, angioedema, urticaria, bronchospasm, anaphylactic reactions, SLE (systemic lupus erythematosus);
• other effects: hyperglycemia, hypercholesterolemia, fecal blockage, severe intestinal obstruction, megacolon; in addition, phenothiazine derivatives can cause glucose intolerance;
• local reactions: i / m introduction - infiltrates; IV injection - phlebitis; contact with the solution on the skin and mucous membranes - irritation.

Overdose

Symptoms of a chlorpromazine overdose may include: areflexia / hyperreflexia, visual impairment, dry mouth, mydriasis, hyperpyrexia (hypothermia), vomiting, muscle stiffness, respiratory depression, pulmonary edema. Cardiotoxic effects - heart failure, arrhythmia, drop in blood pressure, change in the QRS wave, shock, tachycardia, ventricular fibrillation, cardiac arrest. Neurotoxic effects - agitation, seizures, confusion, disorientation, drowsiness, stupor or coma.

In the case of taking high doses of Aminazin, the stomach should be washed and activated charcoal should be taken. It is necessary to avoid the induction of vomiting, because due to overdose of disturbances of consciousness and dystonic reactions from the muscles of the neck and head, aspiration of vomit is possible.

Further (with parenteral overdose - immediately), symptomatic therapy is recommended:

• collaptoid state: parenteral administration of caffeine, cordiamine, mezaton;
• inhibition of the central nervous system without inhibition of the function of the respiratory center: parenteral administration in moderate doses of pervitin, phenamine, caffeine-sodium benzoate (analeptics are contraindicated in patients with depression of the respiratory center);
• neurological complications: a decrease in the dose of chlorpromazine, the use of trihexyphenidil;
• neuroleptic depression: the use of antidepressants and psychostimulants;
• arrhythmias: administration of intravenous phenytoin at a dose of 9–11 mg / kg;
• heart failure: cardiac glycosides;
• a marked decrease in blood pressure: the introduction of intravenous fluids or vasopressor drugs (norepinephrine, phenylephrine). The use of α- and β-adrenergic agonists, for example, epinephrine, should be avoided, since this can lead to a paradoxical decrease in blood pressure due to blockade of α-adrenergic receptors by chlorpromazine;
• convulsions: diazepam. The use of barbiturates should be avoided, as it can lead to subsequent depression of the central nervous system and respiratory depression;
• parkinsonism: the use of diphenyltropine, diphenhydramine;
• hyperthermia, which is one of the symptoms of NMS: parenteral administration of dantrolene.

In addition, for at least five days, it is required to monitor the activity of the central nervous system, cardiovascular system, respiratory function, measure body temperature, it is also recommended to consult a psychiatrist. Dialysis for the elimination of chlorpromazine is ineffective.

special instructions

During therapy with Aminazine, regular monitoring of pulse, blood pressure, liver / kidney function, and blood counts is required. A complete blood count at the beginning of treatment should be carried out weekly, then once every 3-4 months. With a decrease in the number of leukocytes to 3-3.5 × 10 ⁹ / l, and the number of neutrophils to 1.5–2 × 10 ⁹ / l, these indicators should be monitored twice a week, and when leukocytosis and granulocytopenia are diagnosed, the course of treatment should be interrupted …

Before starting to take the drug, the doctor must warn patients that if signs of infectious diseases appear, such as fever, sore throat, etc., it is necessary to immediately inform the specialist about this.

Chlorpromazine is not recommended to be combined with alcohol intake, since chlorpromazine aggravates the depressing effect of ethanol on the central nervous system.

It is necessary to stop taking Aminazine gradually in order to avoid the development of withdrawal syndrome.

In patients with pheochromocytoma, chlorpromazine can give false positive results when determining the concentration of catecholamines in the blood.

Aminazine can provoke photosensitization, so patients need to avoid ultraviolet radiation.

The procedure for parenteral administration of the solution is carried out with the patient lying down in order to avoid a sharp drop in blood pressure after administration of the drug. At the end of the procedure, the patient must remain in the supine position for at least 1.5–2 hours, since with a sharp transition to the vertical position, orthostatic collapse may develop.

It is required to exclude the possibility of getting the solution on the skin and mucous membranes.

Aminazine is a drug that has an inhibitory effect on the central nervous system; when using the recommended doses, it does not cause a hypnotic effect.

An increase in the dose of Aminazine causes not only an increase in general sedation, but also an inhibition of motor-defensive reflexes, a decrease in motor activity and, to some extent, relaxation of skeletal muscles.

Despite the fact that after taking Aminazine in high doses, the reactivity to external and internal stimuli decreases, consciousness is preserved.

Aminazine can be combined with analgesics for persistent pain syndrome, as well as with tranquilizers and hypnotics - for insomnia. Aminazine enhances the effect of the use of hypnotics, painkillers and local anesthetics.

Influence on the ability to drive vehicles and complex mechanisms

During the treatment with Aminazine, it is recommended to refrain from performing potentially hazardous types of work that require increased concentration of attention and high speed of psychomotor reactions.

Application during pregnancy and lactation

Chlorpromazine passes through the placental barrier, is excreted in breast milk during lactation, and prolongs labor. In the course of experiments on animals, it was revealed that chlorpromazine is capable of causing developmental pathologies in the embryofetal period. There is evidence of the potential risk of developing in newborns whose mothers took Aminazine during the third trimester of pregnancy, extrapyramidal disorders and withdrawal syndrome. Due to the use of high doses of chlorpromazine during gestation, in some cases, in newborns, digestive disorders were noted, which are associated with the atropine-like effect of the drug.

In connection with the above, prescribing Aminazin during pregnancy is contraindicated. Breastfeeding should be discontinued during treatment.

Pediatric use

If it is necessary to use chlorpromazine in pediatrics, it is advisable to use special dosage forms intended for children.

Recommended dosage for children: taken orally or administered parenterally (IM) at 550 mcg / kg or 15 mg per 1 m ² of body surface, if necessary, every 6–8 hours.

Dosage adjustment and age restrictions depending on the form of release:

• film-coated tablets: may be used over the age of 12 years; with a child's body weight of no more than 46 kg, the daily dose of the drug should not exceed 75 mg;
• dragee: allowed to be used over the age of 3 years. The daily dose of the drug should not exceed: for children 3-5 years old with a body weight of no more than 23 kg - 40 mg; for children 5–12 years old with a body weight of 23–46 kg - 75 mg;
• solution for intravenous and intramuscular administration: it is allowed to use over the age of 6 months. The daily dose of the drug should not exceed: for children from 6 months to 5 years with a body weight of no more than 23 kg - 40 mg; for children 5–12 years old with a body weight of 23–46 kg - 75 mg.

In pediatric patients, especially in the treatment of acute diseases, the use of phenothiazines increases the likelihood of developing extrapyramidal symptoms.

With impaired renal function

Dragee Aminazine is contraindicated in case of impaired renal function.

A solution for intravenous and intramuscular administration is prescribed with caution to patients with renal insufficiency.

For violations of liver function

All dosage forms of the drug are prescribed with caution at an increased risk of developing hepatotoxic reactions (for example, in patients with active alcoholism).

Dragee Aminazine is contraindicated to take with violations of liver function.

A solution for intravenous and intramuscular administration is prescribed with caution to patients with hepatic insufficiency.

Use in the elderly

The use of phenothiazines in elderly patients increases the risk of excessive hypotensive and sedative effects.

The maximum daily dose of Aminazine for elderly and debilitated patients should not exceed 300 mg.

Drug interactions

• drugs that depress the function of the central nervous system (narcotic analgesics, drugs for general anesthesia, ethanol-containing drugs and alcoholic beverages, tranquilizers, etc.): can increase CNS depression and respiratory depression;
• barbiturates: may reduce serum chlorpromazine;
• analgesics and antipyretics: with prolonged joint use, hyperthermia may develop (undesirable combination);
• tricyclic antidepressants, maprotiline, monoamine oxidase (MAO) inhibitors: increase the likelihood of neuroleptic malignant syndrome;
• epinephrine, other sympathomimetics, antiepileptic drugs: phenothiazine derivatives are their antagonists, can lower the seizure threshold;
• antithyroid drugs: in combination with chlorpromazine, they increase the risk of developing agranulocytosis;
• drugs that cause extrapyramidal reactions: the frequency and severity of extrapyramidal pathologies may increase;
• anesthetics, slow calcium channel blockers, other antihypertensive drugs, trazodone: phenothiazine derivatives enhance their hypotensive efficacy;
• neuronal blockers (guanethidine), amphetamines, clonidine: chlorpromazine inhibits their therapeutic effect;
• angiotensin-converting enzyme (ACE) inhibitors: severe orthostatic hypotension may occur;
• β-blockers: chlorpromazine increases the risk of arterial hypotension, including orthostatic, due to the summation of the decrease in cardiac output caused by β-blockers and the vasodilatory effect of chlorpromazine; the risk of developing tardive dyskinesia, irreversible retinopathy increases;
• antiarrhythmic drugs of Ia and III classes, β-blockers, some calcium channel blockers, digitalis drugs, pilocarpine, anticholinesterase drugs: when combined with chlorpromazine, bradycardia and an increased risk of developing cardiac ventricular tachycardia (including arrhythmias of the "pirouette" type) "); if this combination is necessary, ECG monitoring is recommended;
• nitrates: chlorpromazine enhances the vasodilatory effect, increasing the risk of orthostatic hypotension;
• thiazide diuretics: hyponatremia may increase;
• bromocriptine: chlorpromazine increases the plasma concentration of prolactin, interfering with the action of bromocriptine;
• tricyclic antidepressants, atropine, H ₁ -histaminoblockers, antiparkinsonian anticholinergic (antimuscarinic) antispasmodics, phenothiazine antipsychotics, disopyramide, clozapine, other drugs of anticholinergic action: it is possible to increase such anticholinergic side effects as urine obstruction, dry urine reactions, such as., as well as provocation of an acute attack of glaucoma;
• ephedrine: its vasoconstrictor effect may decrease;
• epinephrine: possible perversion of its action with a decrease in blood pressure; in case of an overdose, the use of epinephrine is not allowed;
• levodopa: chlorpromazine blocks dopamine receptors, thereby reducing its antiparkinsonian effect;
• prochlorperazine (chemically related to chlorpromazine): when used simultaneously, may cause prolonged loss of consciousness;
• antacids and antiparkinsonian drugs: may inhibit the absorption of chlorpromazine; do not take antacids 2 hours before and 2 hours after Aminazin;
• lithium salts: in combination with chlorpromazine, they reduce its absorption, the renal excretion of lithium increases, the risk of extrapyramidal complications increases;
• ototoxic drugs (for example, antibiotics): chlorpromazine can mask some signs of ototoxicity (dizziness, tinnitus);
• other hepatotoxic drugs: increase the risk of developing drug-induced liver damage;
• drugs that inhibit erythropoiesis: the risk of myelosuppression increases;
• antimalarial drugs: increase the plasma concentration of chlorpromazine in the blood and the risk of developing its toxic effects;
• cimetidine: can change (increase / decrease) the level of chlorpromazine in blood plasma;
• hypoglycemic drugs: chlorpromazine in high doses (from 100 mg per day) inhibits their hypoglycemic effect by reducing insulin secretion and increases blood glucose levels;
• other anticholinergic drugs: may enhance the moderate anticholinergic activity of chlorpromazine, or chlorpromazine may increase the anticholinergic effect of other drugs, while its own anticholinergic effect may decrease.

Analogs

Aminazine analogs are Aminazin-Ferein, Chlorpromazine hydrochloride.

Terms and conditions of storage

Keep out of the reach of children. Store tablets and solution in a dark place. Storage temperature: tablets and dragees - no higher than 25 ° С, solution - 5-25 ° С.

Shelf life: tablets - 2 years, pills - 5 years, solution for intravenous and intramuscular administration - 3 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Aminazin

Patients recommend keeping Aminazine in the home medicine cabinet, because, due to its diverse therapeutic effect, it can be used both to reduce highly elevated blood pressure and relieve muscle hypertonia, and as a calming agent with psychomotor agitation. In addition, the drug is effective for soothing prolonged hiccups and as an antiemetic, it can be useful in recovering from withdrawal symptoms.

In most reviews of Aminazine, patients emphasize its high efficacy and good tolerance, provided that all the doctor's recommendations on the dosage regimen are followed. Moderate cost of the drug is also considered an indisputable advantage.

The price of Aminazin in pharmacies

Estimated prices of Aminazin:

• tablets / dragees (10 pcs. in a package): in a dosage of 25 mg - 135–160 rubles, in a dosage of 50 mg - 204–248 rubles, in a dosage of 100 mg - 276–310 rubles;
• solution for intravenous and intramuscular administration (25 mg / ml, 2 ml in an ampoule, 10 ampoules in a package) - 159-190 rubles.

Aminazin: prices in online pharmacies

Drug name Price Pharmacy

Aminazin 25 mg film-coated tablets 10 pcs. 132 RUB Buy

Aminazin tablets p.p. 25mg 10 pcs. 143 r Buy

Aminazin 25 mg / ml solution for intravenous and intramuscular administration 2 ml 10 pcs. RUB 165 Buy

Aminazin 50 mg film-coated tablets 10 pcs. 205 RUB Buy

Aminazine solution for intravenous and intramuscular injection. 2.5% 2ml 10 pcs. 206 RUB Buy

Aminazin tablets p.p. 50mg 10 pcs. 239 r Buy

Aminazin 100 mg film-coated tablets 10 pcs. 287 r Buy

Aminazin 100 mg dragee 10 pcs. 299 r Buy

Aminazin tablets p.p. 100mg 10 pcs. 305 RUB Buy

See all offers from pharmacies

Anna Kozlova Medical journalist About the author

Education: Rostov State Medical University, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!